Razadyne Paragraph IV Certification
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification for Johnson & Johnson's Alzheimer's product Razadyne (galantamine, formerly Reminyl) was filed Feb. 28, according to FDA's May 3 updated list of filings